The Global Brain Cancer drugs market size stood at USD 2.83 billion in 2021 and is expected to rise to USD 5.64 billion by the end of 2028 exhibiting a CAGR of approximately 10.4% during the forecast period.
Brain cancer arises from abnormal proliferation of cells in the brain which occurs as a result of exposure to ionising radiation or other genetic mutations in the body. This is associated with frequent headaches, double vision, hearing and speech abnormalities which impede with the quality of life. This creates opportunities for the pharmaceutical manufacturers to couple new advances in technology with existing treatment modalities to introduce new drugs into the market.
Brain Cancer drugs market in Sweden is mainly driven by the growing incidence and prevalence of neurological disorders. Neurological disorders are highly prevalent owing to their longer life expectancy. This aspect, coupled with the rising geriatric population is promising in terms of market growth. New growth opportunities are on the rise with new drugs in the pipeline for paediatric patients.